Takayuki Takahama

机构：Kindai University Hospital, Kindai University · ORCID：0000-0002-0321-6718

发表论文 115 篇 · 总被引 1801 次 · h-index 21

代表论文

• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024 · Journal of Clinical Oncology · 被引 126)
• Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade (2024 · Journal of Clinical Investigation · 被引 45)
• Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database (2024 · Journal for ImmunoTherapy of Cancer · 被引 7)
• Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. (2024 · Journal of Clinical Oncology · 被引 7)
• A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial) (2024 · Clinical Lung Cancer · 被引 5)
• Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma (2025 · Frontiers in Medicine · 被引 3)